2012 Cancer Advances

“Targeted therapies for metastatic HER2-positive breast cancer are among this year’s top advances in oncology, according to a report from the American Society of Clinical Oncology (ASCO).”

This year, other innovations in cancer have occurred as well.

Slowing disease progression is an important step in treating cancer, and that is what the recently approved drug pertuzumab (Perjeta) appears to do for advanced breast cancer. This happens when combined with another therapy.

Read more:

Targeted Therapy Leads 2012 Cancer Advances